HEALTH RECALL — HEALTHCARE, MENTAL HEALTH & AGING

Check the bottle: one lot of thyroid tablets has been recalled.

This is not a recall of every thyroid medicine—or even every bottle of this product. It covers one lot of Vitruvias Therapeutics Thyroid Tablets, USP 30 mg. Here is exactly what to look for and what the FDA says patients should do next.

Vitruvias Therapeutics voluntarily recalled the lot after testing confirmed that the tablets may be superpotent—meaning they may contain more active thyroid hormone than intended. The company announced the recall on August 21, and the FDA posted it on August 24. The lot was distributed nationwide to the company’s direct accounts between January 31 and September 30, 2025. The announcement does not identify individual Rockland pharmacies or say that every bottle reached a patient. Read the FDA-posted recall notice and view the product label ↗

Do not stop it on your own

The recall notice says patients taking tablets from lot 504950 should not discontinue the medicine without contacting their healthcare provider for guidance or a replacement prescription. If the pharmacy dispensed the tablets in a different container and the lot is not visible, call the dispensing pharmacy and ask it to check the manufacturer and lot tied to the prescription.

What superpotency can cause

Too much thyroid hormone can cause signs of an overactive thyroid, including weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, a rapid heart rate, or an abnormal heart rhythm. The recall identifies older adults, pregnant patients, and infants as groups at greater risk, especially with longer exposure. Anyone who has experienced a problem that may be connected to the medicine should contact a physician or other healthcare provider.

As of the announcement, the company said it had received no reports of adverse events known to be related to this recall. That is not the same as saying the affected tablets are safe to keep taking without professional guidance.

Questions and adverse-event reports

Vitruvias Therapeutics lists (256) 239-9373, Monday through Friday from 9 a.m. to 5 p.m. Central Time, and safety@vitruvias.com for recall questions. Patients and healthcare professionals can also report adverse reactions or product-quality problems through the FDA’s MedWatch program ↗.

The useful version is simple: match the product, strength, NDC, lot, and expiration date—not just the words “thyroid medicine.” If all four details match, contact the prescriber or dispensing pharmacy before changing the dose or stopping treatment.

Source: U.S. Food and Drug Administration recall notice publishing Vitruvias Therapeutics’ August 21, 2026 company announcement. FDA page and MedWatch link checked August 28, 2026, at 12:53 a.m. EDT. This service guide is not individualized medical advice.